Neurizon Therapeutics Ltd
NUZ
Company Profile
Business description
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).
Contact
385 Bourke Street
Suite 2, Level 11
MelbourneVIC3205
AUST: +61 396927222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
52
Stocks News & Analysis
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
stocks
12 picks for an income portfolio - Q1 2026 update
Passive income growth continues to exceed my target.
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.10 | 12.00 | 0.13% |
| CAC 40 | 8,353.31 | 71.82 | -0.85% |
| DAX 40 | 24,457.39 | 244.85 | -0.99% |
| Dow JONES (US) | 49,386.97 | 60.46 | -0.12% |
| FTSE 100 | 10,620.05 | 47.58 | -0.45% |
| HKSE | 26,361.07 | 200.74 | 0.77% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 58,824.89 | 348.99 | 0.60% |
| NZX 50 Index | 12,915.45 | 9.78 | 0.08% |
| S&P 500 | 7,117.10 | 8.96 | -0.13% |
| S&P/ASX 200 | 8,953.30 | 13.60 | 0.15% |
| SSE Composite Index | 4,082.13 | 30.70 | 0.76% |